Repeated drug-eluting stent implantation for drug-eluting stent restenosis: The same or a different stent - 09/08/11
Résumé |
Background |
Currently, little data are available on the management of drug-eluting stent (DES) restenosis. Drug resistance may play a role in its etiology.
Methods |
We identified all cases of either sirolimus-eluting or paclitaxel-eluting stent restenosis treated with repeated DES implantation. The lesions were divided into those receiving the same DES as the one that restenosed and those treated with the alternative DES. The end points analyzed were target lesion revascularization (TLR) and angiographic restenosis.
Results |
We included 201 lesions (174 patients); the same DES was implanted in 107 lesions and a different DES in 94 lesions. Angiographic follow-up of the retreatment was available in 69.7% of the lesions. Angiographic restenosis occurred in 26.4% (19) of cases treated with the same DES and 25.8% (17) of those treated with a different DES (P = 1.0). Target lesion revascularization occurred in 15.9% (17) and 16% (15) of lesions, respectively (P = 1.0). A multivariate analysis confirmed the lack of association between the treatment selected and TLR (OR 0.7, 95% CIs [0.29-1.67]; P = .42). A nonfocal pattern of restenosis remained associated with TLR and restenosis (OR 2.99, 95% CIs [1.24-7.24]; P = .015 and OR 3.6, 95% CIs [1.5-8.8]; P = .004, respectively).
Conclusions |
Repeated DES implantation for DES restenosis is feasible and safe. The TLR rate is acceptable, with no differences between implantation of the same or a different DES. The pattern of restenosis treated is an important predictor of outcomes.
Le texte complet de cet article est disponible en PDF.Plan
| There are no potential conflicts of interest or funding sources to disclose. |
Vol 153 - N° 3
P. 354-359 - mars 2007 Retour au numéro
Article précédent
- Adjunctive mechanical devices to prevent distal embolization in patients undergoing mechanical revascularization for acute myocardial infarction: A meta-analysis of randomized trials
- Giuseppe De Luca, Harry Suryapranata, Gregg W. Stone, David Antoniucci, Franz-Joseph Neumann, Massimo Chiariello
- Early abciximab administration before primary percutaneous coronary intervention improves infarct-related artery patency and left ventricular function in high-risk patients with anterior wall myocardial infarction: A randomized study
- Tomasz Rakowski, Jaroslaw Zalewski, Jacek Legutko, Stanislaw Bartus, Lukasz Rzeszutko, Artur Dziewierz, Danuta Sorysz, Leszek Bryniarski, Krzysztof Zmudka, Grzegorz L. Kaluza, Jacek S. Dubiel, Dariusz Dudek
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?